FDA Approves Lucemyra—But Is It Better Than Clonidine? Carlat Reports

FDA Approves Lucemyra—But Is It Better Than Clonidine?

The Carlat Addiction Treatment Report, Volume 6, Number 8, November 2018
https://www.thecarlatreport.com/newsletter-issue/catrv6n8/

From The Carlat Addiction Treatment Report, November 2018, Opioid Addiction

Issue Links: Learning Objectives | Editorial Information

Topics: News of Note

Joshua Sonkiss, MD

Dr. Sonkiss has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

On May 16, 2018, the FDA announced its approval of Lucemyra (lofexidine) as a drug to help patients withdraw from opioids. Like clonidine, lofexidine is an alpha-2 agonist, but it is touted as causing less orthostatic hypotension and therefore being somewhat safer to use.

You can't view details of this content, please login or buy subscription here